InsightfulValue
โ† Home

Coloplast
Coloplast

-5.92%

Healthcare & biotech / Medical devices and services


๐Ÿ”ง Tools

โœ… Due Diligence
Company at a Glance

More reviews (5)
Coloplast

๐Ÿ“Š Get full analytics about Coloplast

Sign up for free or log in

๐Ÿ“ Join us and grab your copy of "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks"

Price
Live  
Infographic
Infographics
Overview
Coloplast is a Danish medical device company that specializes in the development and production of products for the management of various health conditions, including ostomy, continence, wound care, skin health, and urology. The company was founded in 1957 and is headquartered in Humlebรฆk, Denmark.
Coloplast's mission is to make life easier for people with health conditions by providing innovative and high-quality products that improve their quality of life. The company has a strong focus on research and development, with a team of scientists and engineers constantly working to improve their product offerings.
Coloplast has a global presence, with operations in over 50 countries and distribution in more than 100 countries. The company has approximately 12,000 employees worldwide and reported revenue of DKK 17.842 billion in 2020.
Products of Coloplast
Coloplast offers a wide range of products for ostomy, continence, wound care, skin health, and urology. Some of their most well-known products include:
1. SenSura Mio: A one-piece ostomy pouch system that is designed to fit individual body shapes and provide a secure and comfortable fit.
2. SpeediCath: A ready-to-use intermittent catheter for people with bladder problems, aiming to reduce the risk of urinary tract infections.
3. Biatain: A range of wound dressings that absorb excess wound fluid and provide a moist healing environment.
4. Brava Skin Barrier: A range of skin barrier products designed to protect the skin around a stoma and prevent skin irritation.
5. Conveen: A range of products for managing male urinary incontinence, including external catheters and leg bags.
6. Peristeen: A rectal irrigation system for people with bowel problems, aiming to improve bowel function and reduce the risk of constipation.
7. Arion: A range of skin care products for people with incontinence, designed to protect and soothe the skin.
8. SpeediBag: A range of sterile urine bags for people with bladder problems, designed to be discreet and easy to use.
Overall, Coloplast focuses on providing innovative products that are easy to use, comfortable, and promote better health and quality of life for their customers.
How to explain to a 10 year old kid about the company?
Coloplast

๐Ÿ“ˆ Want to read more about Coloplast?

Sign up for free or log in

๐Ÿ‘ฅ Free eBook for new users: "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks"

Q29sb3BsYX N0IGlzIGEg Y29tcGFueS B0aGF0IGhl bHBzIHBlb3 BsZSB3aG8g aGF2ZSBtZW RpY2FsIG5l ZWRzLiBUaG V5IG1ha2Ug c3BlY2lhbC Bwcm9kdWN0 cyBmb3IgZm 9sa3Mgd2hv IG1pZ2h0IG hhdmUgZGlm ZmljdWx0aW VzIGJlY2F1 c2Ugb2YgdG hpbmdzIGxp a2Ugc3VyZ2 VyaWVzLCBp bmp1cmllcy wgb3IgaGVh bHRoIGlzc3 Vlcy4gRm9y IGV4YW1wbG UsIHRoZXkg ZGVzaWduIG FuZCBzZWxs IHRoaW5ncy BsaWtlIGJh Z3MgZm9yIG NvbGxlY3Rp bmcgdXJpbm Ugb3IgcHJv ZHVjdHMgdG hhdCBoZWxw IHBlb3BsZS BjYXJlIGZv ciB3b3VuZH Mgb3Igc3Rv bWFzICh3aG ljaCBhcmUg b3BlbmluZ3 MgaW4gdGhl IGJvZHkpLi A8YnI+Q29s b3BsYXN0IG 1ha2VzIG1v bmV5IGJ5IH NlbGxpbmcg dGhlc2UgcH JvZHVjdHMg dG8gaG9zcG l0YWxzLCBj bGluaWNzLC BhbmQgcGVv cGxlIHdoby BuZWVkIHRo ZW0uIFRoZX kgd29yayBo YXJkIHRvIG NyZWF0ZSBo aWdoLXF1YW xpdHksIGNv bWZvcnRhYm xlLCBhbmQg ZWFzeS10by 11c2UgaXRl bXMsIHdoaW NoIG1ha2Vz IHBlb3BsZS B3YW50IHRv IGJ1eSBmcm 9tIHRoZW0u PGJyPlRoZS Bjb21wYW55 IGlzIHN1Y2 Nlc3NmdWwg YmVjYXVzZS BpdCBmb2N1 c2VzIG9uIG hlbHBpbmcg cGVvcGxlIG ZlZWwgYmV0 dGVyIGFuZC BsaXZlIHRo ZWlyIGxpdm VzIG1vcmUg ZWFzaWx5Li BUaGV5IGxp c3RlbiB0by B3aGF0IGN1 c3RvbWVycy BuZWVkIGFu ZCBrZWVwIG ltcHJvdmlu ZyB0aGVpci Bwcm9kdWN0 cy4gUGx1cy wgdGhlIHdv cmxkIGhhcy BhIGxvdCBv ZiBwZW9wbG Ugd2hvIG5l ZWQgdGhlc2 Uga2luZHMg b2YgcHJvZH VjdHMsIGFu ZCB0aGF0IG 51bWJlciBp cyBncm93aW 5nIGFzIHBl b3BsZSBsaX ZlIGxvbmdl ciBhbmQgc2 9tZXRpbWVz IG5lZWQgbW 9yZSBoZWxw Ljxicj5Jbi B0aGUgZnV0 dXJlLCBDb2 xvcGxhc3Qg d2lsbCBsaW tlbHkgY29u dGludWUgdG 8gZG8gd2Vs bCBiZWNhdX NlIHRoZXkg YXJlIGFsd2 F5cyBsb29r aW5nIGZvci BuZXcgd2F5 cyB0byBoZW xwIHBlb3Bs ZSBhbmQgaW 1wcm92ZSBo ZWFsdGggY2 FyZS4gVGhl eSBpbnZlc3 QgaW4gcmVz ZWFyY2ggdG 8gZGV2ZWxv cCBiZXR0ZX Igc29sdXRp b25zIGFuZC Bjb25uZWN0 IHdpdGggdX NlcnMgdG8g dW5kZXJzdG FuZCB0aGVp ciBleHBlcm llbmNlcyBi ZXR0ZXIuIE FzIGxvbmcg YXMgdGhleS BrZWVwIGRv aW5nIHRoaX MsIHRoZXkg d2lsbCBsaW tlbHkgcmVt YWluIGEgc3 Ryb25nIGFu ZCBoZWxwZn VsIGNvbXBh bnkuPGJyPg ==
What is special about the company?
Coloplast

๐Ÿ“ˆ Want to read more about Coloplast?

Sign up for free or log in

โœ… Download "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks" โ€” totally free!

MS4gRm9jdX Mgb24gbWVk aWNhbCBkZX ZpY2VzIGFu ZCBzZXJ2aW NlczogQ29s b3BsYXN0IG lzIGEgZ2xv YmFsIGxlYW RlciBpbiB0 aGUgZGV2ZW xvcG1lbnQg YW5kIHByb2 R1Y3Rpb24g b2YgbWVkaW NhbCBkZXZp Y2VzIGFuZC BzZXJ2aWNl cywgc3BlY2 lmaWNhbGx5 IGluIHRoZS BhcmVhcyBv ZiBvc3RvbX ksIHVyb2xv Z3ksIGNvbn RpbmVuY2Us IGFuZCB3b3 VuZCBjYXJl LiBUaGlzIG ZvY3VzIGFs bG93cyB0aG UgY29tcGFu eSB0byBoYX ZlIGEgZGVl cCB1bmRlcn N0YW5kaW5n IG9mIHRoZS BzcGVjaWZp YyBuZWVkcy BhbmQgY2hh bGxlbmdlcy BmYWNlZCBi eSBwYXRpZW 50cyB3aXRo IHRoZXNlIG NvbmRpdGlv bnMgYW5kIG RldmVsb3Ag aW5ub3ZhdG l2ZSBzb2x1 dGlvbnMgdG 8gbWVldCB0 aG9zZSBuZW Vkcy48YnI+ Mi4gUGF0aW VudC1jZW50 cmljIGFwcH JvYWNoOiBD b2xvcGxhc3 QncyBtaXNz aW9uIGlzIH RvIG1ha2Ug bGlmZSBlYX NpZXIgZm9y IHBlb3BsZS B3aXRoIGlu dGltYXRlIG hlYWx0aGNh cmUgbmVlZH MuIFRoZSBj b21wYW55IH Rha2VzIGEg cGF0aWVudC 1jZW50cmlj IGFwcHJvYW NoIGluIGFs bCBhc3BlY3 RzIG9mIGl0 cyBidXNpbm VzcywgZnJv bSBwcm9kdW N0IGRldmVs b3BtZW50IH RvIGN1c3Rv bWVyIHNlcn ZpY2UsIHRv IGVuc3VyZS B0aGUgYmVz dCBwb3NzaW JsZSBjYXJl IGFuZCBvdX Rjb21lcyBm b3IgcGF0aW VudHMuPGJy PjMuIENvbG xhYm9yYXRp dmUgcGFydG 5lcnNoaXBz OiBDb2xvcG xhc3QgY29s bGFib3JhdG VzIHdpdGgg aGVhbHRoY2 FyZSBwcm9m ZXNzaW9uYW xzLCBwYXRp ZW50IG9yZ2 FuaXphdGlv bnMsIGFuZC BvdGhlciBz dGFrZWhvbG RlcnMgdG8g dW5kZXJzdG FuZCB0aGUg bmVlZHMgb2 YgcGF0aWVu dHMgYW5kIG RldmVsb3Ag cHJvZHVjdH MgYW5kIHNl cnZpY2VzIH RoYXQgYWRk cmVzcyB0aG VtLiBUaGlz IGNvbGxhYm 9yYXRpdmUg YXBwcm9hY2 ggZm9zdGVy cyBpbm5vdm F0aW9uIGFu ZCBlbnN1cm VzIHRoYXQg Q29sb3BsYX N0J3Mgc29s dXRpb25zIG FyZSBlZmZl Y3RpdmUgYW 5kIHJlbGV2 YW50Ljxicj 40LiBHbG9i YWwgcHJlc2 VuY2U6IFdp dGggb3Blcm F0aW9ucyBp biBvdmVyID UwIGNvdW50 cmllcyBhbm QgcHJvZHVj dHMgc29sZC BpbiBtb3Jl IHRoYW4gMT AwIGNvdW50 cmllcywgQ2 9sb3BsYXN0 IGhhcyBhIH N0cm9uZyBn bG9iYWwgcH Jlc2VuY2Uu IFRoaXMgYW xsb3dzIHRo ZSBjb21wYW 55IHRvIHJl YWNoIGFuZC BzZXJ2ZSBh IGRpdmVyc2 UgcmFuZ2Ug b2YgcGF0aW VudHMgd29y bGR3aWRlLC BtYWtpbmcg aXQgYSBsZW FkZXIgaW4g dGhlIGludG VybmF0aW9u YWwgaGVhbH RoY2FyZSBp bmR1c3RyeS 48YnI+NS4g U3Ryb25nIG NvbW1pdG1l bnQgdG8gc3 VzdGFpbmFi aWxpdHk6IE NvbG9wbGFz dCBpcyBjb2 1taXR0ZWQg dG8gb3Blcm F0aW5nIHN1 c3RhaW5hYm x5LCBib3Ro IGluIHRlcm 1zIG9mIGl0 cyBlbnZpcm 9ubWVudGFs IGltcGFjdC BhbmQgaXRz IHNvY2lhbC ByZXNwb25z aWJpbGl0eS 4gVGhlIGNv bXBhbnkgaG FzIHNldCBh bWJpdGlvdX MgZ29hbHMg dG8gcmVkdW NlIGl0cyBj YXJib24gZW 1pc3Npb25z LCB3YXRlci Bjb25zdW1w dGlvbiwgYW 5kIHdhc3Rl LCBhcyB3ZW xsIGFzIGlt cHJvdmUgZX RoaWNhbCBw cmFjdGljZX MgdGhyb3Vn aG91dCBpdH Mgc3VwcGx5 IGNoYWluLj xicj42LiBD dWx0dXJlIG 9mIGlubm92 YXRpb246IE NvbG9wbGFz dCBoYXMgYS BzdHJvbmcg Y3VsdHVyZS BvZiBpbm5v dmF0aW9uLC BmdWVsZWQg YnkgaXRzIG RlZGljYXRl ZCB0ZWFtcy BvZiByZXNl YXJjaGVycy BhbmQgZW5n aW5lZXJzLi BUaGUgY29t cGFueSBpbn Zlc3RzIGhl YXZpbHkgaW 4gcmVzZWFy Y2ggYW5kIG RldmVsb3Bt ZW50LCBjb2 5zdGFudGx5 IHNlZWtpbm cgbmV3IGFu ZCBiZXR0ZX Igd2F5cyB0 byBhZGRyZX NzIHRoZSBu ZWVkcyBvZi BwYXRpZW50 cyBhbmQgaW 1wcm92ZSB0 aGVpciBxdW FsaXR5IG9m IGxpZmUuPG JyPjcuIENv cnBvcmF0ZS Bnb3Zlcm5h bmNlIGFuZC ByZXNwb25z aWJpbGl0eT ogQ29sb3Bs YXN0IGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiByZXNw b25zaWJsZS Bjb3Jwb3Jh dGUgZ292ZX JuYW5jZSBh bmQgZXRoaW NhbCBiZWhh dmlvci4gVG hpcyBpbmNs dWRlcyBhcm VhcyBzdWNo IGFzIGNvbX BsaWFuY2Us IHRyYW5zcG FyZW5jeSwg YW5kIGFjY2 91bnRhYmls aXR5LCBhcy B3ZWxsIGFz IGV0aGljYW wgbWFya2V0 aW5nIGFuZC BzYWxlcyBw cmFjdGljZX MuPGJyPjgu IEVtcGxveW VlIGRldmVs b3BtZW50IG FuZCBkaXZl cnNpdHk6IE NvbG9wbGFz dCB2YWx1ZX MgZGl2ZXJz aXR5IGFuZC BpbnZlc3Rz IGluIGl0cy BlbXBsb3ll ZXMnIGRldm Vsb3BtZW50 IGFuZCB3ZW xsLWJlaW5n LiBUaGUgY2 9tcGFueSBv ZmZlcnMgYS B2YXJpZXR5 IG9mIHRyYW luaW5nIGFu ZCBkZXZlbG 9wbWVudCBw cm9ncmFtcy wgYXMgd2Vs bCBhcyBoZW FsdGggYW5k IHdlbGxuZX NzIGluaXRp YXRpdmVzLC B0byBzdXBw b3J0IGl0cy BlbXBsb3ll ZXMnIHBlcn NvbmFsIGFu ZCBwcm9mZX NzaW9uYWwg Z3Jvd3RoLj xicj45LiBB d2FyZHMgYW 5kIHJlY29n bml0aW9uOi BDb2xvcGxh c3QgaGFzIG JlZW4gcmVj b2duaXplZC Bmb3IgaXRz IGV4Y2VsbG VuY2UgaW4g dmFyaW91cy BhcmVhcywg aW5jbHVkaW 5nIHByb2R1 Y3QgaW5ub3 ZhdGlvbiwg c3VzdGFpbm FiaWxpdHks IGFuZCBjb3 Jwb3JhdGUg cmVzcG9uc2 liaWxpdHku IFNvbWUgb2 YgdGhlIGNv bXBhbnkncy Btb3N0IG5v dGFibGUgYX dhcmRzIGlu Y2x1ZGUgRm 9yYmVzJyBN b3N0IElubm 92YXRpdmUg R3Jvd3RoIE NvbXBhbmll cyBhbmQgQ2 9ycG9yYXRl IEtuaWdodH MnIEdsb2Jh bCAxMDAgTW 9zdCBTdXN0 YWluYWJsZS BDb3Jwb3Jh dGlvbnMuPG JyPjEwLiBD b21taXRtZW 50IHRvIG1h a2luZyBhIH Bvc2l0aXZl IGltcGFjdD ogQWJvdmUg YWxsLCBDb2 xvcGxhc3Qg aXMgYSBjb2 1wYW55IHRo YXQgaXMgY2 9tbWl0dGVk IHRvIG1ha2 luZyBhIHBv c2l0aXZlIG ltcGFjdCBp biB0aGUgd2 9ybGQgYW5k IGltcHJvdm luZyB0aGUg bGl2ZXMgb2 YgcGF0aWVu dHMuIFRoaX MgY29yZSB2 YWx1ZSBkcm l2ZXMgdGhl IGNvbXBhbn kncyBhY3Rp b25zIGFuZC BkZWNpc2lv bnMsIG1ha2 luZyBpdCBh IHNwZWNpYW wgYW5kIHJl cHV0YWJsZS Bvcmdhbml6 YXRpb24u
What the company's business model?
Coloplast

๐Ÿ“ˆ Want to read more about Coloplast?

Sign up for free or log in

โœ… Download "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks" โ€” totally free!

VGhlIENvbG 9wbGFzdCBj b21wYW55J3 MgYnVzaW5l c3MgbW9kZW wgaXMgYnVp bHQgb24gdG hyZWUgcGls bGFyczogSW 5ub3ZhdGlv biwgY3VzdG 9tZXIgZm9j dXMsIGFuZC BzdXN0YWlu YWJpbGl0eS 4gVGhleSBz cGVjaWFsaX plIGluIGRl c2lnbmluZy wgbWFudWZh Y3R1cmluZy wgYW5kIGRp c3RyaWJ1dG luZyBtZWRp Y2FsIGRldm ljZXMgYW5k IHNlcnZpY2 VzIGZvciBw ZW9wbGUgd2 l0aCBpbnRp bWF0ZSBoZW FsdGhjYXJl IG5lZWRzLi BUaGVpciBi dXNpbmVzcy Btb2RlbCBm b2N1c2VzIG 9uIGRldmVs b3BpbmcgaW 5ub3ZhdGl2 ZSBzb2x1dG lvbnMgaW4g dXJvbG9neS wgY29udGlu ZW5jZSwgYW 5kIHdvdW5k IGNhcmUgdG 8gaW1wcm92 ZSB0aGUgcX VhbGl0eSBv ZiBsaWZlIG ZvciB0aGVp ciBjdXN0b2 1lcnMuIFRo ZXkgYWxzby BzdHJpdmUg dG8gbWFpbn RhaW4gYSBz dHJvbmcgY3 VzdG9tZXIg Zm9jdXMgYn kgY29sbGFi b3JhdGluZy B3aXRoIGhl YWx0aGNhcm UgcHJvZmVz c2lvbmFscy BhbmQgZW5n YWdpbmcgd2 l0aCB0aGVp ciBjdXN0b2 1lcnMgdG8g dW5kZXJzdG FuZCB0aGVp ciBuZWVkcy BhbmQgcHJv dmlkZSBwZX Jzb25hbGl6 ZWQgc29sdX Rpb25zLiBB ZGRpdGlvbm FsbHksIHN1 c3RhaW5hYm lsaXR5IGlz IGEga2V5IG NvbXBvbmVu dCBvZiB0aG VpciBidXNp bmVzcyBtb2 RlbCwgZW1w aGFzaXppbm cgcmVzcG9u c2libGUgYW 5kIGV0aGlj YWwgcHJhY3 RpY2VzIGlu IHRoZWlyIG 9wZXJhdGlv bnMgdG8gY3 JlYXRlIGEg cG9zaXRpdm UgaW1wYWN0 IG9uIHRoZS BlbnZpcm9u bWVudCBhbm Qgc29jaWV0 eS4=
Is AI a threat?
AI can have several implications for the Coloplast company, which specializes in medical devices and products for personal healthcare, particularly in areas like wound care, ostomy care, continence care, and urology. Examining the potential threats through substitution, disintermediation, or margin pressure provides a clearer picture.
1. Substitution: AI-driven innovations could lead to the development of alternative therapeutic approaches or substitutes for Coloplastโ€™s products. For instance, advancements in smart wearables, biosensors, or telehealth platforms may offer new ways for patients to monitor their conditions effectively without relying solely on traditional medical devices. If these alternatives prove to be more effective or convenient, Coloplast could face challenges in retaining its market share.
2. Disintermediation: AI can streamline processes in healthcare delivery, potentially reducing the need for intermediaries like distributors or even healthcare providers in some contexts. If AI tools empower patients to manage their care more autonomously, it could disrupt the conventional channels through which Coloplastโ€™s products are marketed and sold. This shift could affect Coloplastโ€™s relationships with healthcare professionals and the overall sales strategy.
3. Margin Pressure: The integration of AI could drive efficiency and lower costs in the healthcare industry. As competitors leverage AI to reduce production costs, enhance product functionality, or improve customer service, Coloplast may face pressure to lower its prices or enhance its offerings, impacting profit margins. Additionally, if AI facilitates the entry of new, agile players into the market, competition could further intensify.
Overall, while AI presents opportunities for innovation and improvement in healthcare, it also poses potential threats to Coloplastโ€™s products, services, and competitive positioning. The company would need to actively engage with these developments and adapt its strategy to mitigate risks associated with substitution, disintermediation, and margin pressure.
Sensitivity to interest rates
The sensitivity of Coloplastโ€™s earnings, cash flow, and valuation to changes in interest rates can be analyzed through various financial and operational aspects:
1. Earnings Sensitivity:
Changes in interest rates can influence Coloplastโ€™s cost of borrowing. If interest rates rise, the cost of debt servicing may increase, potentially decreasing net income. Conversely, lower interest rates could reduce borrowing costs, positively influencing earnings. Additionally, since Coloplast operates globally, fluctuations in interest rates can also impact demand for its medical products in different markets, affecting overall sales and profitability.
2. Cash Flow Sensitivity:
Interest rate changes directly affect cash flow generation, especially if Coloplast has significant outstanding debt. Higher rates increase cash outflows related to interest payments, which could strain operational cash flows. Furthermore, if interest rates rise, consumer spending may decline due to increased financing costs, impacting Coloplastโ€™s sales and, in turn, its cash flow. On the other hand, lower rates could stimulate economic activity, potentially enhancing cash flow from increased product demand.
3. Valuation Sensitivity:
The valuation of Coloplast, often assessed through discounted cash flow (DCF) models, is sensitive to interest rates. Higher interest rates raise the discount rate applied to future cash flows, reducing present value estimates and potentially leading to lower valuations. Conversely, lower rates decrease the discount rate, enhancing the present value of expected future cash flows and supporting a higher valuation.
In summary, Coloplastโ€™s earnings, cash flow, and valuation are sensitive to changes in interest rates, primarily through the effects on borrowing costs, operational performance, consumer demand, and the discount rate applied in valuation models. Understanding these sensitivities is crucial for investors and analysts monitoring the companyโ€™s financial health and market position.
Resilience to the future changes
Coloplast

๐Ÿ“ˆ Want to read more about Coloplast?

Sign up for free or log in

๐ŸŽ Free download! "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks"

QSByZWFsaX N0aWMgc2Nl bmFyaW8gdG hhdCBjb3Vs ZCBwZXJtYW 5lbnRseSBp bXBhaXIgQ2 9sb3BsYXN0 4oCZcyBlY2 9ub21pY3Mg b3ZlciB0aG UgbmV4dCAz LTUgeWVhcn MgaXMgdGhl IGludHJvZH VjdGlvbiBv ZiBzdHJpbm dlbnQgcmVn dWxhdG9yeS BjaGFuZ2Vz IGluIGtleS BtYXJrZXRz LCBwYXJ0aW N1bGFybHkg aW4gRXVyb3 BlIGFuZCBO b3J0aCBBbW VyaWNhLCB3 aGljaCBzaW duaWZpY2Fu dGx5IHJhaX NlcyB0aGUg Y29zdCBvZi Bjb21wbGlh bmNlIGZvci BtZWRpY2Fs IGRldmljZS BtYW51ZmFj dHVyZXJzLi BUaGVzZSBy ZWd1bGF0aW 9ucyBjb3Vs ZCBpbnZvbH ZlIG1vcmUg cmlnb3JvdX MgYXBwcm92 YWwgcHJvY2 Vzc2VzIGZv ciBuZXcgcH JvZHVjdHMs IGluY3JlYX NlZCB0ZXN0 aW5nIHJlcX VpcmVtZW50 cywgb3IgdG lnaHRlciBj b250cm9scy BvbiBtYW51 ZmFjdHVyaW 5nIHByb2Nl c3Nlcy48Yn I+SW4gc3Vj aCBhIHNjZW 5hcmlvLCBD b2xvcGxhc3 QgbWlnaHQg ZXhwZXJpZW 5jZSBzZXZl cmFsIGFkdm Vyc2UgZWZm ZWN0cy4gRm lyc3QsIHRo ZSBpbmNyZW FzZWQgY29t cGxpYW5jZS Bjb3N0cyBj b3VsZCBsZW FkIHRvIGEg c3Vic3Rhbn RpYWwgcmVk dWN0aW9uIG luIG9wZXJh dGluZyBtYX JnaW5zLiBJ ZiB0aGUgY2 9tcGFueeKA mXMgY29zdC BvZiBnb29k cyBzb2xkIH Jpc2VzIGR1 ZSB0byByZX F1aXJlZCBp bnZlc3RtZW 50cyBpbiBx dWFsaXR5IG Fzc3VyYW5j ZSBhbmQgcm VndWxhdG9y eSBjb21wbG lhbmNlLCBv dmVyYWxsIH Byb2ZpdGFi aWxpdHkgY2 91bGQgZGVj bGluZS4gRm 9yIGV4YW1w bGUsIGlmIG 9wZXJhdGlu ZyBtYXJnaW 5zIHdlcmUg dG8gZHJvcC Bmcm9tIDMw JSB0byBhcm 91bmQgMjAl LCB0aGUgY2 9tcGFueeKA mXMgYWJpbG l0eSB0byBn ZW5lcmF0ZS Bwcm9maXQg ZnJvbSBpdH Mgc2FsZXMg d291bGQgYm UgYWR2ZXJz ZWx5IGFmZm VjdGVkLjxi cj5TZWNvbm QsIGNhc2gg ZmxvdyBjb3 VsZCBhbHNv IHRha2UgYS BoaXQuIEhp Z2hlciBvcG VyYXRpbmcg Y29zdHMgY2 91cGxlZCB3 aXRoIHBvc3 NpYmxlIGRl bGF5cyBpbi Bwcm9kdWN0 IGxhdW5jaG VzIGR1ZSB0 byByZWd1bG F0b3J5IGh1 cmRsZXMgY2 91bGQgbGVh ZCB0byBzdG FnbmF0aW9u IGluIHJldm VudWUgZ3Jv d3RoLiBJZi BDb2xvcGxh c3TigJlzIG Nhc2ggZmxv dyBmcm9tIG 9wZXJhdGlv bnMgd2VyZS B0byBkZWNy ZWFzZSBzaW duaWZpY2Fu dGx54oCUZn JvbSwgc2F5 LCAxNSUgb2 YgcmV2ZW51 ZSB0byBhcm 91bmQgNSXi gJR0aGUgY2 9tcGFueSB3 b3VsZCBoYX ZlIGxlc3Mg ZmxleGliaW xpdHkgdG8g aW52ZXN0IG luIGdyb3d0 aCBvcHBvcn R1bml0aWVz IG9yIHJldH VybiBjYXBp dGFsIHRvIH NoYXJlaG9s ZGVycy48Yn I+TGFzdGx5 LCB0aGUgYm FsYW5jZSBz aGVldCBjb3 VsZCByZWZs ZWN0IHRoZS BzdHJhaW4g ZnJvbSB0aG VzZSBhZHZl cnNlIGVjb2 5vbWljIGNv bmRpdGlvbn MuIEluY3Jl YXNlZCBjb3 N0cyBtYXkg bGVhZCBDb2 xvcGxhc3Qg dG8gdGFrZS BvbiBkZWJ0 IHRvIGZpbm FuY2UgY29t cGxpYW5jZS 1yZWxhdGVk IGV4cGVuZG l0dXJlcyBv ciB0byBtYW 5hZ2UgY2Fz aCBmbG93IH RpZ2h0bmVz cy4gQXMgYS ByZXN1bHQs IHRoZSBjb2 1wYW554oCZ cyBsZXZlcm FnZSByYXRp b3MgY291bG Qgd29yc2Vu LCB3aXRoIG RlYnQtdG8t ZXF1aXR5IH JhdGlvcyBy aXNpbmcsIH B1dHRpbmcg cHJlc3N1cm Ugb24gY3Jl ZGl0IHJhdG luZ3MuIFRo aXMgY291bG QgZnVydGhl ciBsaW1pdC BhY2Nlc3Mg dG8gY2FwaX RhbCBhbmQg aW5jcmVhc2 UgYm9ycm93 aW5nIGNvc3 RzLjxicj5J biBzdW1tYX J5LCBpZiBz dHJpbmdlbn QgcmVndWxh dG9yeSBjaG FuZ2VzIGxl ZCB0byBhIG RlY2xpbmUg aW4gbWFyZ2 lucywgcmVk dWNlZCBjYX NoIGZsb3cs IGFuZCBhIH dlYWtlbmVk IGJhbGFuY2 Ugc2hlZXQs IENvbG9wbG FzdCB3b3Vs ZCBoYXZlIH RvIG5hdmln YXRlIGEgY2 9uc2lkZXJh Ymx5IHJpc2 tpZXIgb3Bl cmF0aW9uYW wgbGFuZHNj YXBlLCBwb3 RlbnRpYWxs eSBpbXBhY3 RpbmcgaXRz IGxvbmctdG VybSBncm93 dGggdHJham VjdG9yeSBh bmQgbWFya2 V0IHBvc2l0 aW9uLjxicj 4=
Interesting facts about the company
Coloplast

๐Ÿ“ˆ Want to read more about Coloplast?

Sign up for free or log in

๐Ÿ†“ Discover "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks" โ€” free eBook!

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvcE l5V3VvM2JY VkQ1T0trQm lxcGEud2Vi cCIgYWx0PS JDb2xvcGxh c3QiIHRpdG xlPSJDb2xv cGxhc3QiIC BjbGFzcz0i aW1nLWZsdW lkIiBoZWln aHQ9NTAgd2 lkdGg9NTAg bG9hZGluZz 0nbGF6eScg c3R5bGU9J2 JvcmRlci1y YWRpdXM6ID ZweDsnPgoK ICAgICAgIC AgICAgICAg ICAgICA8ZG l2IHN0eWxl PSdmbGV4Oi AxOyB0ZXh0 LWFsaWduOi BjZW50ZXI7 IG1hcmdpbi 1sZWZ0OiA1 cHg7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PHAgc3R5bG U9J2ZvbnQt c2l6ZTogMj ZweDsgY29s b3I6ICMzMz M7IG1hcmdp bi1ib3R0b2 06IDE1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IPCfk4ggV2 FudCB0byBy ZWFkIG1vcm UgYWJvdXQg Q29sb3BsYX N0PwogICAg ICAgICAgIC AgICAgICAg ICAgICA8L3 A+CgogICAg ICAgICAgIC AgICAgICAg ICAgICA8YS BocmVmPSdp bmRleC5waH A/cGFnZT1z aWdudXAnIH N0eWxlPScK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJh Y2tncm91bm QtY29sb3I6 ICMwMDdCRk Y7CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Bjb2xvcjog I2ZmZjsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIHBhZG Rpbmc6IDEw cHggMjBweD sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG JvcmRlci1y YWRpdXM6ID VweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHRleHQt ZGVjb3JhdG lvbjogbm9u ZTsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGZvbnQtd2 VpZ2h0OiBi b2xkOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgbWFyZ2 luLXJpZ2h0 OiAxMHB4Ow ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgdH JhbnNpdGlv bjogYmFja2 dyb3VuZC1j b2xvciAwLj NzIGVhc2U7 JwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg b25tb3VzZW 92ZXI9J3Ro aXMuc3R5bG UuYmFja2dy b3VuZENvbG 9yPSIjMDA1 NmIzIicKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIG9ubW 91c2VvdXQ9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA3QkZGIi c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BTaWduIHVw IGZvciBmcm VlCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvYT 4KCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxzcG FuIHN0eWxl PSdtYXJnaW 46IDAgOHB4 OyBjb2xvcj ogIzU1NTsn Pm9yPC9zcG FuPgoKICAg ICAgICAgIC AgICAgICAg ICAgICAgPG EgaHJlZj0n aW5kZXgucG hwP3BhZ2U9 bG9naW4nIH N0eWxlPScK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGNv bG9yOiAjMD A3QkZGOwog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdGV4 dC1kZWNvcm F0aW9uOiB1 bmRlcmxpbm U7CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Bmb250LXdl aWdodDogNT AwOyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBsb2cg aW4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9h PgoKCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxw IHN0eWxlPS dtYXJnaW4t dG9wOiAxNX B4OyBmb250 LXNpemU6ID EzcHg7IGZv bnQtd2VpZ2 h0OiBib2xk OyBjb2xvcj ogI2QzMmYy ZjsnPgogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAg8J+TpS BHZXQgb3Vy IGZyZWUgZU Jvb2sgbm93 OiA8aT4iVG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcy I8L2k+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvcD4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID whLS0KICAg ICAgICAgIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nbWFyZ2 luLXRvcDog MTJweDsgZm 9udC1zaXpl OiAxM3B4Oy Bjb2xvcjog IzQ0NDsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgU2 lnbiB1cCBu b3cgYW5kIG dldCBvdXIg ZnJlZSBlQm 9vayAKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIDxiPlRo ZSBDaGVja2 xpc3QgVmFs dWUgSW52ZX N0b3Ig4oCU IEEgU21hcn RlciBXYXkg dG8gUGljay BTdG9ja3M8 L2I+CiAgIC AgICAgICAg ICAgICAgIC AgICAgIDwv ZGl2PgogIC AgICAgICAg ICAgICAgIC AgICAgICAt LT4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPCEt LQogICAgIC AgICAgICAg ICAgICAgIC AgICA8ZGl2 IHN0eWxlPS dtYXJnaW4t dG9wOiAxNn B4OyBmb250 LXNpemU6ID E0cHg7IGNv bG9yOiAjND Q0OyBmb250 LWZhbWlseT ogLWFwcGxl LXN5c3RlbS wgQmxpbmtN YWNTeXN0ZW 1Gb250LCBT ZWdvZSBVSS wgUm9ib3Rv LCBIZWx2ZX RpY2EgTmV1 ZSwgc2Fucy 1zZXJpZjsg bGluZS1oZW lnaHQ6IDEu NjsnPgogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgSGF2ZS B5b3UgaGVh cmQgYWJvdX Qgb3VyIHNo b3J0IDxzdH Jvbmcgc3R5 bGU9J2Zvbn Qtd2VpZ2h0 OiA2MDA7Jz 5EYWlseSBW aWRlbyBOZX dzbGV0dGVy PC9zdHJvbm c+PwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naHR0cH M6Ly93d3cu aW5zaWdodG Z1bHZhbHVl LmNvbS9uZX dzbGV0dGVy LnBocCcgdG FyZ2V0PSdf YmxhbmsnIH N0eWxlPSdj b2xvcjogIz AwN0JGRjsg dGV4dC1kZW NvcmF0aW9u OiBub25lOy Bmb250LXdl aWdodDogNT AwOyBtYXJn aW4tbGVmdD ogNnB4Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgRmluZC BvdXQgbW9y ZQogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgICAgIC AgICAgICAg LS0+CiAgIC AgICAgICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgIAogICAg ICAgIAogIC AgICAgIDxz cGFuIGNsYX NzPSdibHVy cmVkLXRleH QnPgogICAg ICAgICAgIC BNUzRnUTI5 c2IzIEJzWV hOMElIZGgg Y3lCbWIzVn VaRyBWa0lH bHVJREU1IE 5UY2dhVzRn UkcgVnViV0 Z5YXlCaSBl U0JCWVdkbE lFIHh2ZFds ekxVaGggYm 5ObGJpd2dk MiBodklIZG hjeUJ0IGIz UnBkbUYwWl cgUWdZbmtn YUdseiBJRz kzYmlCbGVI IEJsY21sbG JtTmwgSUhk cGRHZ2dZVy A0Z2IzTjBi MjE1IExpQT hZbkkrTWkg NGdWR2hsSU dOdiBiWEJo Ym5uaWdKIG x6SUdacGNu TjAgSUhCeW IyUjFZMyBR Z2QyRnpJR0 VnIGNHeGhj M1JwWXkgQn ZjM1J2Ylhr ZyBZbUZuTE NCMGFHIFVn NG9DY1EyOX MgYjNCc1lY TjBJRSA5em RHOXRlU0JD IFlXY3M0b0 NkSUggZG9h V05vSUVGaC BaMlVnVEc5 MWFYIE10U0 dGdWMyVnUg SUdSbGMybG 5ibSBWa0lH aHBiWE5sIG JHWWdZVzVr SUcgMWhjbX RsZEdWayBJ SFJ2SUd4dl kyIEZzSUdo dmMzQnAgZE dGc2N5NGdQ RyBKeVBqTX VJRlJvIFpT QmpiMjF3WV cgNTU0b0Na Y3lCdSBZVz FsSUhkaGN5 IEJqYUc5el pXNGcgWVhN Z1lTQmpiMi AxaWFXNWhk R2x2IGJpQn ZaaUIwYUcg VWdkMjl5Wk hNZyA0b0Nj UTI5c2FYIF JwYytLQW5T QW8gWVNCam IyMXRiMiA0 Z1kyOXVaR2 wwIGFXOXVJ R1p2Y2kgQn ZjM1J2Ylhr ZyBjR0YwYV dWdWRIIE1w SUdGdVpDRG kgZ0p4d2JH RnpkRyBsaj RvQ2RJQ2gw IGFHVWdiV0 YwWlggSnBZ V3dnZFhObC BaQ0JwYmlC MGFHIFZwY2 lCd2NtOWsg ZFdOMGN5a3 VJRCB4aWNq NDBMaUJKIG JpQXhPVGsz TEMgQkRiMn h2Y0d4aCBj M1FnWW1Wal lXIDFsSUhS b1pTQm0gYV hKemRDQmpi MiAxd1lXNT VJR2x1IElI Um9aU0IzYj MgSnNaQ0Iw YnlCayBaWF psYkc5d0lH IEZ1SUc5em RHOXQgZVNC aVlXY2dkMi BsMGFDQmhi aUJwIGJuUm xaM0poZEcg VmtJSE5yYV c0ZyBZbUZ5 Y21sbGNpIH dnYldGcmFX NW4gSUhSb1 pTQmlZVyBj Z1pXRnphV1 Z5IElHRnVa Q0J4ZFcgbG phMlZ5SUhS diBJR05vWV c1blpTIDRn UEdKeVBqVX UgSUVOdmJH OXdiRyBGem RDQjNZWE1n IGIyNWxJRz ltSUggUm9a U0JtYVhKei BkQ0JqYjIx d1lXIDVwWl hNZ2RHOGcg ZFhObElFbH VjMyBSaFoz SmhiU0JtIG IzSWdZMjl5 Y0cgOXlZWF JsSUcxaCBj bXRsZEdsdV p5IHdnYzNS aGNuUnAgYm 1jZ2FXNGdN aiBBeE1pNG dQR0p5IFBq WXVJRlJvWl MgQmpiMjF3 WVc1NSBJRz l3WlhKaGRH IFZ6SUdsdU lHOTIgWlhJ Z05UQWdZMi A5MWJuUnlh V1Z6IElHRn VaQ0JvWVgg TWdiVzl5Wl NCMCBhR0Z1 SURFd0xEIE F3TUNCbGJY QnMgYjNsbF pYTWdkMiA5 eWJHUjNhV1 JsIExpQThZ bkkrTnkgNG dRMjlzYjNC cyBZWE4wNG 9DWmN5IEJq YjNKd2IzSm ggZEdVZ2FH VmhaSCBGMV lYSjBaWEln IGFYTWdiRz lqWVggUmxa Q0JwYmlCSS BkVzFzWldK aFpXIHNzSU VSbGJtMWgg Y21zc0lHSj FkQyBCMGFH VWdZMjl0IG NHRnVlU0Jv WVggTWdabU ZqYVd4cCBk R2xsY3lCaG JtIFFnYjJa bWFXTmwgY3 lCcGJpQmpi MyBWdWRISn BaWE1nIFlY SnZkVzVrSU ggUm9aU0Iz YjNKcyBaQ3 dnYVc1amJI IFZrYVc1bk lIUm8gWlNC VmJtbDBaVy BRZ1UzUmhk R1Z6IExDQk RZVzVoWkcg RXNJRU5vYV c1aCBMQ0Jo Ym1RZ1UyID kxZEdnZ1FX WnkgYVdOaE xpQThZbiBJ K09DNGdTVz RnIE1qQXlN Q3dnUm0gOX lZbVZ6SUc1 aCBiV1ZrSU VOdmJHIDl3 YkdGemRDQm ggY3lCdmJt VWdiMiBZZ2 RHaGxJSGR2 IGNteGs0b0 NaY3kgQnRi M04wSUdsdS BibTkyWVhS cGRtIFVnWT I5dGNHRnUg YVdWekxpQT hZbiBJK09T NGdRMjlzIG IzQnNZWE4w SUcgbHpJR0 VnYkdWaCBa R1Z5SUdsdU lHIFJsZG1W c2IzQnAgYm 1jZ2IzTjBi MiAxNUxDQj FjbTlzIGIy ZDVMQ0JqYj IgNTBhVzVs Ym1ObCBMQ0 JoYm1RZ2Qy IDkxYm1RZ1 kyRnkgWlNC d2NtOWtkVy BOMGN5d2dZ blYwIElIUm 9aU0JqYjIg MXdZVzU1SU dGcyBjMjhn YjJabVpYIE p6SUhCeWIy UjEgWTNSek lHbHVJRyA5 MGFHVnlJR0 Z5IFpXRnpJ SE4xWTIgZ2 dZWE1nYzJ0 cCBiaUJvWl dGc2RHIGdn WVc1a0lHbH UgZEdWeWRt VnVkRyBsdm JtRnNJSFZ5 IGIyeHZaM2 t1SUQgeGlj ajR4TUM0Zy BTVzRnWVdS a2FYIFJwYj I0Z2RHOGcg YldWa2FXTm hiQyBCd2Nt OWtkV04wIG N5d2dRMjlz YjMgQnNZWE 4wSUdGcyBj MjhnYjJabV pYIEp6SUhO MWNIQnYgY2 5RZ2MyVnlk bSBsalpYTW dabTl5IElH OXpkRzl0ZV MgQndZWFJw Wlc1MCBjeX dnYVc1amJI IFZrYVc1bk lHRnUgSUc5 dWJHbHVaUy BCamIyMXRk VzVwIGRIa2 dZVzVrSUcg RWdiVzlpYV d4bCBJR0Z3 Y0NCbWIzIE lnZEhKaFky dHAgYm1jZ1 lXNWtJRyAx aGJtRm5hVz VuIElHOXpk Rzl0ZVMgQn pkWEJ3Ykds bCBjeTQ9Ci AgICAgICAg PC9zcGFuPg ogICAgICAg IAogICAgIC AgIA==
See Company Q&A
Coloplast

๐Ÿ“Š Get full analytics about Coloplast

Sign up for free or log in

๐Ÿ†“ Discover "The Checklist Value Investor โ€” A Smarter Way to Pick Stocks" โ€” free eBook!

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal